Subscribe
Core coverageNTLA

Company profile / NTLA

Intellia Therapeutics

Clinaptis stanceConstructive
ConvictionMedium
Ticker
NTLA
Exchange
NASDAQ
Coverage
Standard profile
Updated
Oct 3, 2026
Gene Editing / CRISPR

Clinical-stage gene editing company focused on developing in vivo CRISPR-based therapies delivered systemically for severe diseases.

01 / Clinaptis view

The current read

Intellia offers an unusually attractive risk-adjusted setup after the reset in expectations. Lonvo-z has already delivered compelling randomized Phase 3 efficacy in HAE and is approaching a March 2027 PDUFA, while the current enterprise value leaves limited room for a successful HAE franchise plus meaningful nex-z optionality.

  1. We do not assume that permanent editing will rapidly displace effective chronic prophylaxis: patient willingness, payer acceptance and prevalent-pool exhaustion should constrain the HAE commercial curve. Nex-z also deserves a substantial safety and efficacy discount following the liver signal and the less favorable read-through from CARDIO-TTRansform.
  2. Even after those haircuts, however, the current valuation appears attractive relative to the combined value of a de-risked HAE asset and heavily discounted ATTR optionality.
02 / Consensus gap

Where the market may differ

The market is correctly skeptical about adoption of irreversible editing, but at the current valuation it may be charging that skepticism twice: once against lonvo-z commercialization in HAE and again against nex-z optionality in ATTR. Lonvo-z does not need to convert the entire treated HAE population to support substantial value, while nex-z does not need to be valued as a conventional successful ATTR program to contribute meaningful upside.

  1. The key disagreement is therefore not whether permanent editing carries real commercial and safety constraints, but whether those risks justify discounting both lead assets as heavily as the current enterprise value appears to imply.
Coverage state
Standard profile
What the review turns on
Key variable

Regulatory outcome

Next catalyst

Lonvo-z · FDA acceptance of BLA for hereditary angioedema · 2H 2026

03 / Pipeline

Key programs

2 assets · 2 programs

AssetIndicationStageNext event
Lonvoguran ziclumeran (lonvo-z; NTLA-2002)
Hereditary angioedema
BLA preparation
FDA acceptance of BLA expected in 2H 2026
Nexiguran ziclumeran (nex-z; NTLA-2001)
Transthyretin amyloidosis
Phase 3
MAGNITUDE-2 enrollment completion expected in 2H 2026
04 / Connected research

Published on NTLA

View full archive
No published research attached

The profile is live. The research connection is still open.

When a Clinaptis article includes NTLA in its research metadata, it will appear here automatically.

Browse all research